NASDAQ$ANIP

ANI Pharmaceuticals Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

ANI Pharmaceuticals reported a net loss of $12.3 million and adjusted non-GAAP diluted earnings per share of $0.69 for Q2 2020.

ANI Pharmaceuticals reported a decrease in net revenues to $48.5 million for the second quarter of 2020, compared to $54.5 million in the same period of 2019. The company experienced a net loss of $12.3 million, compared to a net income of $6.6 million in the prior year period. Adjusted non-GAAP diluted earnings per share was $0.69, down from $1.44 in the second quarter of 2019. The results were impacted by the COVID-19 pandemic and increased operating expenses.

  • Net revenues for Q2 2020 were $48.5 million, compared to $54.5 million in Q2 2019.
  • Net loss for Q2 2020 was $12.3 million, compared to net income of $6.6 million in the prior year period.
  • Adjusted non-GAAP diluted earnings per share was $0.69 in Q2 2020, compared to $1.44 in the prior year period.
  • Nikhil Lalwani was named President and CEO, effective September 8, 2020.

Headline financials

Total Revenue

$48.5M

Previous: $54.4M-10.8%
EPS (adj)

$0.69

Previous: $1.44-52.1%
Capital Expenditures

-$2.26M

Previous: -$3.41M+33.6%
Free Cash Flow

-$14.6M

Previous: $3.18M-559.7%
Net Income

-$12.3M

Previous: $6.59M-287.3%
Operating Income

-$11.3M

Previous: $9.29M-221.7%
Gross Profit

$27.8M

Previous: $38.7M-28.3%
Cash & Equivalents

$27.7M

Previous: $40.6M-31.7%
Total Assets

$465M

Previous: $447M+4.1%
Stock-Based Comp

$5.74M

Previous: $2.59M+121.2%

Revenue & EPS history

ANI Pharmaceuticals · Revenue · Quarterly

$48.5M

Q2 2020-10.8%vs Q2 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

ANI Pharmaceuticals · $44M total across 2 segments · Q2 2020

  • Generic Products
    $33.4M-8.0%
  • Brands
    $10.6M-24.3%

Forward guidance

Due to inherent uncertainties regarding the duration and impact of the COVID-19 pandemic, ANI has suspended its previously announced 2020 financial guidance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

-1.2%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

38%

24 / 64 earnings

Positive

+52.1%

Q3 2021

Best reaction

-24.6%

Q4 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.4%-3.7%-3.4%
Q4 2025-3.9%-0.8%-5.6%
Q3 2025+0.4%-3.3%-9.4%
Q1 2025-7.5%-15.6%-13.4%
Q4 2024+13.4%+6.3%+10.7%
Q3 2024+5.8%+2.5%-2.4%
Q2 2024-3.6%-2.1%+2.7%
Q1 2024+2.2%-1.6%+1.3%
Q4 2023+11.4%-0.2%+3.0%
Q3 2023-17.9%-18.8%-23.1%
Q2 2023+8.4%+9.2%+10.7%
Q1 2023+13.5%+6.5%+26.2%
Q4 2022-5.3%-6.0%-11.5%
Q3 2022-5.1%-4.7%+3.2%
Q2 2022-1.8%+8.2%+7.3%
Q1 2022-5.9%+1.3%+6.9%
Q4 2021-24.6%-23.6%-9.8%
Q3 2021+52.1%+33.8%+8.2%
Q2 2021-7.9%-8.5%-11.5%
Q1 2021-6.0%-4.1%-1.8%
Q4 2020+4.1%+6.6%+5.3%
Q3 2020-15.9%-3.5%+4.1%
Q2 2020-2.0%+0.7%-6.0%
Q1 2020-7.0%-12.1%-13.0%
Q4 2019-19.1%-8.1%-41.2%
Q3 2019-22.2%-27.3%-24.7%
Q2 2019-10.8%-13.7%-21.0%
Q1 2019+3.1%-1.7%-0.3%
Q4 2018+7.7%+0.1%+8.6%
Q3 2018+7.2%+2.1%-0.2%
Q2 2018-13.0%-13.1%-13.7%
Q1 2018+3.9%+3.9%+9.6%
Q4 2017+11.3%-3.8%+0.6%
Q3 2017+7.7%+4.2%+22.8%
Q2 2017-2.9%-3.8%+6.3%
Q1 2017-2.0%+0.7%-10.3%
Q4 2016-16.3%-18.0%-17.2%
Q3 2016-18.8%-18.0%-2.1%
Q2 2016+10.0%+12.6%-3.6%
Q1 2016+6.4%
Q4 2015+9.1%
Q3 2015-4.4%
Q2 2015-14.0%
Q1 2015-15.4%
Q4 2014+4.0%
Q3 2014+27.1%
Q2 2014+9.7%
Q1 2014-3.3%
Q2 2013-3.0%
Q4 2013+24.9%
Q3 2013+4.2%
Q4 2012+0.0%
Q3 2012-0.8%
Q2 2012-15.5%
Q1 2012-15.4%
Q2 2011+0.0%
Q4 2011+0.0%
Q4 2009+0.0%
Q3 2011-6.0%
Q4 2010-7.2%
Q2 2010-7.2%
Q1 2011+0.9%
Q3 2010-6.3%
Q1 2010-5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro